FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 57 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2017. The put-call ratio across all filers is 21.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $37,309,000 | +9.5% | 11,203,881 | 0.0% | 0.74% | -19.3% |
Q3 2019 | $34,060,000 | +207.0% | 11,203,881 | +140.3% | 0.92% | +260.0% |
Q2 2019 | $11,095,000 | -36.5% | 4,661,824 | 0.0% | 0.26% | -48.3% |
Q1 2019 | $17,482,000 | +10.3% | 4,661,824 | 0.0% | 0.49% | -18.2% |
Q4 2018 | $15,850,000 | -11.0% | 4,661,824 | +50.0% | 0.60% | +26.7% |
Q3 2018 | $17,806,000 | +218.1% | 3,107,424 | +178.1% | 0.48% | +223.8% |
Q2 2018 | $5,598,000 | -2.3% | 1,117,324 | 0.0% | 0.15% | -8.7% |
Q1 2018 | $5,732,000 | -14.6% | 1,117,324 | 0.0% | 0.16% | -27.8% |
Q4 2017 | $6,715,000 | -45.9% | 1,117,324 | -50.0% | 0.22% | -5.9% |
Q3 2017 | $12,402,000 | +139.2% | 2,234,648 | +100.0% | 0.24% | -9.2% |
Q2 2017 | $5,184,000 | -20.8% | 1,117,324 | -15.5% | 0.26% | -30.0% |
Q1 2017 | $6,549,000 | -55.4% | 1,322,994 | 0.0% | 0.37% | -64.3% |
Q4 2016 | $14,685,000 | +15.5% | 1,322,994 | -3.7% | 1.04% | +27.2% |
Q3 2016 | $12,717,000 | +151.9% | 1,373,284 | +72.7% | 0.82% | +134.6% |
Q2 2016 | $5,048,000 | – | 795,000 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |